Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting April 24, 2024
Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization January 5, 2024
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B December 11, 2023
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics November 1, 2023
Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning October 30, 2023
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems May 19, 2023
